Please use this identifier to cite or link to this item:
https://scholarbank.nus.edu.sg/handle/10635/132792
DC Field | Value | |
---|---|---|
dc.title | Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics | |
dc.contributor.author | Dan, Y.-Y. | |
dc.contributor.author | Wai, C.-T. | |
dc.contributor.author | Lee, Y.-M. | |
dc.contributor.author | Sutedja, D.S. | |
dc.contributor.author | Seet, B.-L. | |
dc.contributor.author | Lim, S.-G. | |
dc.date.accessioned | 2016-12-13T05:36:35Z | |
dc.date.available | 2016-12-13T05:36:35Z | |
dc.date.issued | 2005-07-28 | |
dc.identifier.citation | Dan, Y.-Y., Wai, C.-T., Lee, Y.-M., Sutedja, D.S., Seet, B.-L., Lim, S.-G. (2005-07-28). Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World Journal of Gastroenterology 11 (28) : 4344-4350. ScholarBank@NUS Repository. | |
dc.identifier.issn | 10079327 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/132792 | |
dc.description.abstract | Aim: We set to determine factors that determine clinical severity after the development of resistance. Methods: Thirty-five Asian patients with genotypic lamivudine resistance were analyzed in three groups: 13/35 (37%) were non-cirrhotics with normal pre-treatment ALT (Group IA), 12/35 (34%) were non-cirrhotics with elevated pre-treatment ALT (Group IB), and 10/35 (29%) were cirrhotics (Group II). Patients were followed for a median of 98 wk (range 26-220) after the emergence of genotypic resistance. Results: Group IA patients tended to retain normal ALT. Group IB patients showed initial improvement of ALT with lamivudine but 9/12 patients (75%) developed abnormal ALT subsequently. On follow-up however, this persisted in only 33%. Group II patients also showed improvement while on treatment, but they deteriorated with the emergence of resistance with 30% death from decompensated liver disease. Pretreatment ALT levels and CPT score (in the cirrhotic group) were predictive of clinical resistance and correlated with peak ALT levels and CPT score. Conclusion: The phenotype of lamivudine-resistant HBV correlated with the pretreatment phenotype. The clinical course was generally benign in non-cirrhotics. However, cirrhotics had a high risk of progression and death (30%) with the development of lamivudine resistance. © 2005 The WJG Press and Elsevier Inc. All rights reserved. | |
dc.source | Scopus | |
dc.subject | Hepatitis B treatment | |
dc.subject | Lamivudine resistance | |
dc.subject | Nucleoside analog | |
dc.subject | YMDD mutants | |
dc.type | Article | |
dc.contributor.department | MEDICINE | |
dc.description.sourcetitle | World Journal of Gastroenterology | |
dc.description.volume | 11 | |
dc.description.issue | 28 | |
dc.description.page | 4344-4350 | |
dc.description.coden | WJGAF | |
dc.identifier.isiut | NOT_IN_WOS | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.